A transdermal drug delivery patch according to an exemplary embodiment of the present invention includes: a flexible base layer; and a plurality of microneedle disposed at one surface of the base layer. Each of the plurality of microneedles includes a biodegradable polymer and a drug and has an empty space inside. Each of the plurality of microneedles is formed as a star-shaped pyramid including a plurality of protrusions extending in a radial direction, and a part between two protrusions adjacent along the circumferential direction among the plurality of protrusions is concave.

A polyurethane-polyorganosiloxane copolymer is useful as a film forming agent in personal care compositions, such as hair care compositions and skin care compositions.

A silicone urethane urea copolymer and methods for preparation and use of the copolymer are disclosed. The copolymer is crosslinkable. The copolymer is useful in various applications, including personal care compositions, such as hair care compositions and skin care compositions and in health care compositions such as skin contact adhesive compositions and transdermal drug delivery systems.

An adhesive polymer matrix for the delivery of an active principle via iontophoresis. The matrix having a first face intended to be applied onto skin and a second face intended to cooperate with electrodes. The matrix comprises electrically conductive zones and at least one electrically insulating zone, each conductive zone being insulated from another conductive zone by an insulating zone. The techniques involve the use of an electric current in order to facilitate the transdermal diffusion of active substances, and relates more particularly to an iontophoresis device.

A method for creating a multi-antigen patch, comprising providing one or more transdermal patch sheets having a plurality of single dose transdermal patches residing thereon, wherein each one of the plurality of single dose transdermal patches includes an antigen at a particular dilution level disposed within a carrier, removing one or more of the plurality of single dose transdermal patches from the one or more transdermal patch sheets, adhering the one or more of the plurality of single dose transdermal patches to a backing, wherein the backing allows for multiple single dose transdermal patches to be adjacently adhered thereon, and covering the plurality of transdermal patches adhered to the backing with a peelable release liner.

The present disclosure relates to the transdermal administration of cannabidiol (CBD) for the reduction of seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE).

A medical device for the treatment of papilloma virus (HPV) skin infections is the object of this invention, in particular for the treatment of warts and related pathologies. In particular, this invention relates to acetylsalicylic acid for use in the topical treatment, of HPV skin infections in particular benign infections and more in particular warts. Acetylsalicylic acid may be administered by plaster or patch, both in a solid state, such as a tablet, powder or granulate, and by a hydrophilic or hydrophobic gel.

Systems and methods for treatment of hyperuricemia through the application of a base compound, such as, e.g., an antacid or alkali, are presented. Examples of an antacid or alkali includes, e.g., calcium carbonate, aluminum hydroxide, magnesium hydroxide, and sodium bicarbonate. The application uses a transdermal patch for preventing, minimizing or reversing hyperuricemia. The active ingredient or agent, e.g. antacid or alkali, may be distributed in the patch in any suitable manner. For example, a specified amount of the active ingredient or agent may be contained in a single drug-containing layer or multiple drug-containing layers. In addition to the active ingredient or agent, the drug-containing layer may comprise a carrier material for carrying the active ingredient or agent. The active ingredient or agent may be mixed with the carrier material, such as, e.g. homogenously blended, heterogeneously dispersed, encapsulated within, or any combination thereof.

Disclosed is a method for inhibiting degradation of asenapine or a pharmaceutically acceptable salt thereof in a patch. The patch comprises an adhesive layer on a base, and the adhesive layer contains an adhesive base and asenapine or a pharmaceutically acceptable salt thereof. The method includes incorporating at least one amine compound selected from the group consisting of monoethanolamine, diethanolamine, diisopropanolamine, isopropanolamine, triethanolamine and meglumine in the adhesive layer.

A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains an adhesive base and an antioxidant containing a sulfur atom in its molecule.